Pillstats
Rx only · Capsule, Gelatin Coated · Oral

Amantadine Hydrochloride

Amantadine Hydrochloride

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCN04BB01
RxCUI (US)620
US makers2 labelers
Packages4
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.047$0.093$0.140$0.187Dec 2025Apr 2026Jul 2026
$0.154
Latest avg · Jul 22, 2026
-1%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

1633254886512025 Q12025 Q22025 Q32025 Q42026 Q1
56
Rx · 2026 Q1
3.4K
Units dispensed
-90%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 1 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Marlex Pharmaceuticals Incunknown2SUPPLYING
Upsher-Smith Laboratories, LLCunknown2EXITED 2026

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jul 23, 2025
    RESOLVEDShortage resolved: Amantadine Hydrochloride Capsule (Upsher-Smith Laboratories, LLC)

    Amantadine Hydrochloride Capsule — reported in shortage by Upsher-Smith Laboratories, LLC. Therapeutic category: Antiviral, Neurology.

  • Jul 23, 2025
    SHORTAGEDrug shortage: Amantadine Hydrochloride Capsule (Upsher-Smith Laboratories, LLC)

    Amantadine Hydrochloride Capsule — reported in shortage by Upsher-Smith Laboratories, LLC. Therapeutic category: Antiviral, Neurology.